The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Krasnov V.S.

Pavlov First St. Petersburg State Medical University

Makshakov G.S.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Kalinin I.V.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Laskova K.K.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Shumilina M.V.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Evdoshenko E.P.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Totolyan N.A.

Academician I.P. Pavlov First Saint Petersburg State Medical University

Comorbidity of neuromyelitis optica spectrum disorder and systemic lupus erythematosus

Authors:

Krasnov V.S., Makshakov G.S., Kalinin I.V., Laskova K.K., Shumilina M.V., Evdoshenko E.P., Totolyan N.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7): 102‑108

DOI: 10.17116/jnevro2020120071102

Read: 2812 times

Download PDF (RU)
Contact the author
Table of contents

COMORBIDITY OF NEUROMYELITIS OPTICA SPECTRUM DISORDER AND SYSTEMIC LUPUS ERYTHEMATOSUS
COMORBIDITY OF NEUROMYELITIS OPTICA SPECTRUM DISORDER AND SYSTEMIC LUPUS ERYTHEMATOSUS

To cite this article:

Krasnov VS, Makshakov GS, Kalinin IV, Laskova KK, Shumilina MV, Evdoshenko EP, Totolyan NA. Comorbidity of neuromyelitis optica spectrum disorder and systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):102‑108. (In Russ.)
https://doi.org/10.17116/jnevro2020120071102

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Features of depressive diso­rders and suicidal beha­vior in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):7-13
Atte­ntion defi­cit hype­ractivity diso­rder: pharmacotherapy in special situations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):59-65
Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cere­bral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):75-84
Effi­cacy of dupi­lumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):204-209
Review and reso­lution of the Council of Expe­rts on the topic «The role of the combination of unde­natured type II collagen UC-II, vita­min C, and trace elements in reco­vering and maintaining the function of the musculoskeletal system, and preservation of health of the joints». Russian Journal of Preventive Medi­cine. 2025;(4):102-110
Prognostic factors for progression and risk chro­nic obstructive pulmonary disease adve­rse outcomes. Journal of Respiratory Medi­cine. 2025;(2):71-78
Expe­rience in the use of electro- and radio-surgical appa­ratus with no-therapy in the combined treatment of decu­bital ulcers in como­rbid patients of multidisciplinary hospitals, including ICUs. Piro­gov Russian Journal of Surgery. 2025;(11):86-93
Regional living conditions as risk factors for como­rbid conditions deve­lopment in the Russian Fede­ration regions’ elde­rly popu­lations. Russian Journal of Preventive Medi­cine. 2025;(11):23-35
Age-related features of como­rbidity in the presence of chro­nic non-communicable diseases risk factors: obesity, arte­rial hype­rtension, hype­rtriglyceridemia. Russian Journal of Preventive Medi­cine. 2025;(11):45-51
Como­rbidity in patients with obstructive sleep apnea. Part 1. Gene­ral issues. Russian Journal of Preventive Medi­cine. 2025;(11):94-99
Abstract:

The comorbidity of neuromyelitis optica spectrum disorder (NMOSD) and systemic lupus erythematosus (SLE) is a poorly studied problem. The issues of the pathogenetic relationship between these diseases, timely diagnosis of their co-existence in one patient, disease course and therapeutic approaches are the most relevant. The authors summarize current views on the state of the problem and analyze three clinical cases of NMOSD and SLE comorbidity including the diagnostic issues and therapeutic approaches.

Keywords:

neuromyelitis optica spectrum disorder
systemic lupus erythematosus
comorbidity

Authors:

Krasnov V.S.

Pavlov First St. Petersburg State Medical University

Makshakov G.S.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Kalinin I.V.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Laskova K.K.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Shumilina M.V.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Evdoshenko E.P.

St.Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No.31

Totolyan N.A.

Academician I.P. Pavlov First Saint Petersburg State Medical University

Received:

19.01.2020

Accepted:

21.01.2020

Close metadata

References:

  1. Whittam D, Wilson M, Hamid S, Keir G, Bhojak M, Jacob A. What’s new in neuromyelitis optica? A short review for clinical neurologist. Journal of Neurology. 2017;264(11):2330-2344. https://doi.org/10.1007/s00415-017-8445-8
  2. Wingerchuk DM, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.  https://doi.org/10.1212/WNL.0000000000001729
  3. Bruscolini A, Sacchetti M, Cava M, Gharbiya M, Ralli M, Lambiase A, De Virgilio A, Greco A. Diagnosis and management of neuromyelitis optica spectrum disorders-An update. Autoimmunity Reviews. 2018;17(3):195-200.  https://doi.org/10.1016/j.autrev.2018.01.001
  4. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Multiple Sclerosis Journal. 2012;18(1):5-10.  https://doi.org/10.1177/1352458511431077
  5. Bibic VC, Brust TB, Burton JM. Neuromyelitis optica spectrum disorder presenting with concurrent autoimmune disease. Multiple Sclerosis and Related Disorders. 2019;28:125-128.  https://doi.org/10.1016/j.msard.2018.12.028
  6. Shahmohammadia S, Doostia R, Shahmohammadia A, Mohammadianinejad SE, Sahraiana MA, Azimia AR, Harirchianc MH, Asgarid N, Moghadasia AN. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: a literature review. Multiple Sclerosis and Related Disorders. 2019;27:350-363.  https://doi.org/10.1016/j.msard.2018.11.008
  7. Polgar A, Rozsa C, Müller V, Matolcsi J, Poor G, Virág Kiss E. Devic’s syndrome and SLE challenges in diagnosis and therapeutic possibilities based on two overlapping cases. Autoimmunity Reviews. 2011;10(3):171-174.  https://doi.org/10.1016/j.autrev.2010.09.021
  8. Katsumata Y, Kawachi I, Kawaguchi Y, Gono T, Ichida H, Hara M, Yamanaka H. Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. Modern Rheumatology. 2012;22(5):676-684.  https://doi.org/10.1007/s10165-011-0572-y
  9. Yachoui R, Kolasinski SL, Han BK. Intractable vomiting as an initial presentation of lupus-related neuromyelitis optica. Journal of Clinical Rheumatology. 2013;19(3):154-155.  https://doi.org/10.1097/RHU.0b013e318289df02
  10. Adawi M, Bisharat B, Bowirrat A. Systemic Lupus Erythematosus (SLE) complicated by neuromyelitis optica (NMO — Devic’s Disease): clinic-pathological report and review of the literature. Clinical Medicine Insights Case Reports. 2014;7:41-47.  https://doi.org/10.4137/CCRep.S15177
  11. Piga M, Chessa E, Peltz MT, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmunity Review. 2017;16(3):244-252.  https://doi.org/10.1016/j.autrev.2017.01.011
  12. Ajmeraa MR, Boscoeb A, Mauskopfa J, Candrillia SD, Levyc M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. Journal of the Neurological Sciences. 2018;384:96-103.  https://doi.org/10.1016/j.jns.2017.11.022
  13. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and Rheumatism. 1999;42(4):599-608. https://doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F "> 3.0.CO;2-F" target="_blank">https://doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F
  14. Hanly JG, Kozora E, Beyea S, Birnbaum J. Nervous system disease in Systemic Lupus Erythematosus: current status and future directions. Arthritis & Rheumatology. 2019;71(1):33-42.  https://doi.org/10.1002/art.40591
  15. Jacobi C, Stingele K, Kretz R, Hartmann M, Storch-Hagenlocher B, Breitbart A, Wildemann B. Neuromyelitis optica (Devic’s syndrome) as first manifestation of systemic lupus erythematosus. Lupus. 2006;15(2):107-109.  https://doi.org/10.1191/0961203306lu2265cr
  16. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG. Neuromyelitis optica and non-organ — specific autoimmunity. Archives of Neurology. 2008;65:78-83.  https://doi.org/10.1001/archneurol.2007.17
  17. Giorgi D, Balacco Gabrieli C, Bonomo L. The association of optic neuropathy with transverse myelitis in systemic lupus nerythematosus. Rheumatology (Oxford, England). 1999;38:191-192.  https://doi.org/10.1093/rheumatology/38.2.191
  18. Lehnhardt FG, Impekoven P, Rubbert A, Burghaus L, Neveling M, Heiss WD, Jacobs AH. Recurrent longitudinal myelitis as primary manifestation of SLE. Neurology. 2004;63(10):1976. https://doi.org/10.1212/01.wnl.0000140623.47437.b3
  19. Krishnan AV, Halmagyi GM. Acute transverse myelitis in SLE. Neurology. 2004;62(11):2087. https://doi.org/10.1212/01.wnl.0000123089.25458.90
  20. Chan AY, Liu DT. Devic’s syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome. Rheumatology. 2006;45(1):120-121.  https://doi.org/10.1093/rheumatology/kei146
  21. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112. https://doi.org/10.1016/S0140-6736(04)17551-X
  22. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. The Lancet Neurology. 2007;6(9):805-815.  https://doi.org/10.1016/S1474-4422(07)70216-8
  23. Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Current Opinion in Rheumatology. 2019;31(3):250-255.  https://doi.org/10.1097/BOR.0000000000000603
  24. Suárez HF, Urrutia ED, Canales PF, Gutiérrez OC. Neuromyelitis optica presenting concomitantly with systemic lupus erythematosus. Report of one case. Revista Medica de Chile. 2016;144(9):1226-1229. https://doi.org/10.4067/S0034-98872016000900020
  25. Furtado I, Pinheiro G, Campar A, Mendonça T. Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge. BMJ Case Reports. 2018. Jun 4;2018:bcr2017222139. https://doi.org/10.1136/bcr-2017-222139
  26. Han J, Yang M, Zhu J, Jin T. Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations. Neurolpsychiatric Disease and Treatment. 2017;13:2653-2660. https://doi.org/10.2147/NDT.S147360
  27. Petri M, Orbai A-M, Alarcón G, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg D,Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae S-C, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, RuizIrastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G, Magder LS. Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatism. 2012;64(8):2677-2686. https://doi.org/10.1002/art.34473
  28. Kovacs KT, Kalluri SC, Boza-Serrano A, Deierborg T, Csepany T, Simo M, Rokusz L, Miseta A, Alcaraz N, Czirjak L, Berki T, Molnar T, Hemmer B, Illes Z. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. Multiple Sclerosis. 2016;22(9):1192-1201. https://doi.org/10.1177/1352458515613165
  29. Vertkin AL, Rumyancev MA, Skotnikov AS. Comorbidity. Clinical Medicine. 2012;10:4-11. (In Russ.).
  30. Bortoluzzi A, Scire CA, Bombardieri S, Caniatti L, Conti F, De Vita S, Doria A, Ferraccioli G, Gremese E, Mansutti E, Mathieu A, Mosca M, Padovan M, Piga M, Tincani A, Tola MR, Tomietto P, Valesini G, Zen M, Govoni M; Study Group on Neuropsychiatric Systemic Lupus Erythematosus of the Italian Society of Rheumatology. Development and validation of a new algorithm for attribu-tion of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-898.  https://doi.org/10.1093/rheumatology/keu384
  31. Li X-Y, Xiao H-B, Pai P. Myelitis in systemic lupus erythematosus. Journal of Clinical Neuroscience. 2017;44:18-22.  https://doi.org/10.1016/j.jocn.2017.06.003
  32. Pizova NV. Headache, seizures, cognitive disorders, and cerebrovascular disease as the most common neuropsychic syndromes in systemic lupus erythematosus. Rheumatology Science and Practice. 2014;52(2):222-227.  https://doi.org/10.14412/1995-4484-2014-222-227
  33. Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23(6):661-683.  https://doi.org/10.1111/bpa.12084
  34. Sato DK, Nakashina I, Takahashi T, Misu T, Waters P, Kuroda H, Nishiyama S, Suzuki C, Takai Y, Fujihara K, Itoyama Y, Aoki M. Aquaporine-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. 2013;80:2210-2216. https://doi.org/10.1212/WNL.0b013e318296ea08
  35. Waters P, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporine-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290-303.  https://doi.org/10.1111/cen3.12107
  36. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016;76(4):459-483.  https://doi.org/10.1007/s40265-015-0534-3
  37. Sá MJ. Acute transverse myelitis: a practical reappraisal. Autoimmunity Reviews. 2009;9(2):128-131.  https://doi.org/10.1016/j.autrev.2009.04.005
  38. Asgari N, Jarius S, Laustrup H, Skejoe HPB, Lillevang ST, Weinshenker BG, Voss A. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Multiple Sclerosis. 2017;24:331-339.  https://doi.org/10.1177/1352458517699791
  39. Thabah MM, Sekar D, Pranov R, Moulitej MMV, Ramesh A, Kadhiravan T. Neuromyelitis optica spectrum disorder and systemic lupus erythematosus. Lupus. 2019;28(14):1722-1726. https://doi.org/10.1177/0961203319888692
  40. Simaniv TO, Vorob’eva AA, Smirnova NV, Zigangirova NA, Zakharova MN. Neuromyelitis optica and aquaporin-associated syndrome. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(2 Pt 2):31-37. (In Russ.).
  41. Shidahara K, Hayashi K, Sada KE, Hiramatsu S, Morishita M, Watanabe H, Matsumoto Y, Kawabata T, Wada J. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab. Lupus. 2018;27(8):1374-1377. https://doi.org/10.1177/0961203318760994
  42. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. The Journal of Rheumatology. 2008;35(1):172-174. 
  43. Nasir S, Kerr DA, Birnbaum J. Nineteen episodes of recurrentmyelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Archives of Neurology. 2009;66(9):1160-1163. https://doi.org/10.1001/archneurol.2009.194
  44. Rossijskie klinicheskie rekomendacii. Revmatologiya. Pod red. Nasonova E.L. M.: Izdatel’stvo GEOTER-Media; 2017. (In Russ.).
  45. Trebst C, Kümpfel T. Neuroimmunology and rheumatology: overlap and differential diagnoses. Der Nervenarzt. 2018;89(10):1095-1105. https://doi.org/10.1007/s00115-018-0597-y
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.